Evidence map›Paper›PMID 25674466›Full record

ReviewSpringerPlus2014

Diminished mTOR signaling: a common mode of action for endocrine longevity factors.

Dudley W Lamming

Open access · diamondAbstract readReview
In one paragraph

Review in SpringerPlus, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.

  1. Cellular and Molecular Pathophysiology of Gestational Diabetes.International journal of molecular sciences · 2024
    Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. microRNA-449a reduces growth hormone-stimulated senescent cell burden through PI3K-mTOR signaling.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  9. Article
  10. The central moTOR of metabolism.Developmental cell · 2022
    Review
  11. Article
  12. Review
  13. Review
  14. Aging and Protein Kinases.Advances in experimental medicine and biology · 2021
    Article
  15. Article
  16. Review
  17. Article
  18. Next Generation Strategies for Geroprotection via mTORC1 Inhibition.The journals of gerontology. Series A, Biological sciences and medical sciences · 2020
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Dudley W LammingDivision of Endocrinology, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin USA ; William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin USA.
University of Wisconsin–Madison · US

Funding

The in vivo regulation of glucose homeostasis and lifespan by mTORC2R00AG041765 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI LAMMING, DUDLEY WILLIAM · 2014 to 2016
$738k
The in vivo regulation of glucose homeostasis and lifespan by mTORC2K99AG041765 · NIA · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI LAMMING, DUDLEY WILLIAM · 2012 to 2013
$141k
NIA NIH HHS K99 AG041765NIA NIH HHS R00 AG041765
6 · The paper itself

Abstract

Since the initial observation that a calorie-restricted (CR) diet can extend rodent lifespan, many genetic and pharmaceutical interventions that also extend lifespan in mammals have been discovered. The mechanism by which CR and these other interventions extend lifespan is the subject of significant debate and research. One proposed mechanism is that CR promotes longevity by increasing insulin sensitivity, but recent findings that dissociate longevity and insulin sensitivity cast doubt on this hypothesis. These findings can be reconciled if longevity is promoted not via increased insulin sensitivity, but instead via decreased PI3K/Akt/mTOR pathway signaling. This review presents a unifying hypothesis that explains the lifespan-extending effects of a variety of genetic mutations and pharmaceutical interventions and points towards new molecular pathways which may also be leveraged to promote healthy aging.

Indexed as

Calorie restrictionInsulin resistanceLongevityRapamycin

Identifiers

PMID25674466
PMCPMC4320218
OpenAlexW2129099193

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.